title: Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica.
abstract: Eosinophils are abundant in inflammatory demyelinating lesions in neuromyelitis optica (NMO). We used cell culture, ex vivo spinal cord slices, and in vivo mouse models of NMO to investigate the role of eosinophils in NMO pathogenesis and the therapeutic potential of eosinophil inhibitors. Eosinophils cultured from mouse bone marrow produced antibody-dependent cell-mediated cytotoxicity (ADCC) in cell cultures expressing aquaporin-4 in the presence of NMO autoantibody (NMO-IgG). In the presence of complement, eosinophils greatly increased cell killing by a complement-dependent cell-mediated cytotoxicity (CDCC) mechanism. NMO pathology was produced in NMO-IgG-treated spinal cord slice cultures by inclusion of eosinophils or their granule toxins. The second-generation antihistamines cetirizine and ketotifen, which have eosinophil-stabilizing actions, greatly reduced NMO-IgG/eosinophil-dependent cytotoxicity and NMO pathology. In live mice, demyelinating NMO lesions produced by continuous intracerebral injection of NMO-IgG and complement showed marked eosinophil infiltration. Lesion severity was increased in transgenic hypereosinophilic mice. Lesion severity was reduced in mice made hypoeosinophilic by anti-IL-5 antibody or by gene deletion, and in normal mice receiving cetirizine orally. Our results implicate the involvement of eosinophils in NMO pathogenesis by ADCC and CDCC mechanisms and suggest the therapeutic utility of approved eosinophil-stabilizing drugs.
authors.affiliation: Department of Medicine, UCSF, San Francisco, California 94143-0521, USA.
authors.forename: Hua
authors.initials: H
authors.lastname: Zhang
authors.forename: A S
authors.initials: AS
authors.lastname: Verkman
mesh_terms: D000818:Animals; D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology*; D051401:Aquaporin 4 / Q000378:metabolism; D001323:Autoantibodies / Q000276:immunology; D001854:Bone Marrow Cells / Q000166:cytology; D003165:Complement System Proteins / Q000276:immunology; D004195:Disease Models, Animal; D047209:Eosinophil Peroxidase / Q000378:metabolism; D004804:Eosinophils / Q000166:cytology* / Q000473:pathology; D007074:Immunoglobulin G / Q000737:chemistry; D007150:Immunohistochemistry; D051379:Mice; D008807:Mice, Inbred BALB C; D008822:Mice, Transgenic; D009471:Neuromyelitis Optica / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D013116:Spinal Cord / Q000378:metabolism
chemical_list: D051401:Aquaporin 4; D001323:Autoantibodies; D007074:Immunoglobulin G; D003165:Complement System Proteins; D047209:Eosinophil Peroxidase
references.citation: Neurology. 2011 Apr 5;76(14):1229-37
references.pmid: 21368286
references.citation: Ann Neurol. 2009 Nov;66(5):617-29
references.pmid: 19938104
references.citation: FASEB J. 2011 Feb;25(2):561-8
references.pmid: 20959515
references.citation: Brain. 2002 Jul;125(Pt 7):1450-61
references.pmid: 12076996
references.citation: Pharmacol Rev. 1999 Jun;51(2):213-340
references.pmid: 10353986
references.citation: Glia. 2012 Dec;60(12):2027-39
references.pmid: 22987455
references.citation: Cancer Res. 2011 Aug 1;71(15):5134-43
references.pmid: 21697279
references.citation: Ther Apher Dial. 2009 Dec;13(6):505-8
references.pmid: 19954473
references.citation: J Allergy Clin Immunol. 1989 Oct;84(4 Pt 1):457-64
references.pmid: 2571627
references.citation: Leuk Lymphoma. 2010 Jul;51(7):1293-304
references.pmid: 20377308
references.citation: J Immunol. 2010 Sep 15;185(6):3472-80
references.pmid: 20693421
references.citation: Ann Neurol. 2012 Mar;71(3):323-33
references.pmid: 22374891
references.citation: Acta Neuropathol. 2012 Jun;123(6):861-72
references.pmid: 22526022
references.citation: Semin Cancer Biol. 2012 Feb;22(1):3-13
references.pmid: 22245472
references.citation: J Immunol. 2010 Jun 1;184(11):6327-34
references.pmid: 20421642
references.citation: J Immunol. 2008 Sep 15;181(6):4004-9
references.pmid: 18768855
references.citation: Brain. 2010 Feb;133(Pt 2):349-61
references.pmid: 20047900
references.citation: J Inflamm (Lond). 2010 Aug 04;7:39
references.pmid: 20682082
references.citation: Drugs. 1993 Dec;46(6):1055-80
references.pmid: 7510611
references.citation: Annu Rev Immunol. 2006;24:147-74
references.pmid: 16551246
references.citation: Brain. 2007 May;130(Pt 5):1224-34
references.pmid: 17405762
references.citation: Mult Scler. 2007 Jun;13(5):679-82
references.pmid: 17548452
references.citation: Nat Clin Pract Neurol. 2008 Apr;4(4):202-14
references.pmid: 18334978
references.citation: Lancet Neurol. 2007 Sep;6(9):805-15
references.pmid: 17706564
references.citation: Mult Scler. 2012 Dec;18(12):1801-3
references.pmid: 22495946
references.citation: J Immunol. 1990 Nov 1;145(9):2950-8
references.pmid: 1698867
references.citation: Lancet Neurol. 2012 Jun;11(6):535-44
references.pmid: 22608667
references.citation: J Biol Chem. 2012 Apr 20;287(17):13829-39
references.pmid: 22393049
references.citation: Nat Rev Drug Discov. 2013 Feb;12(2):117-29
references.pmid: 23334207
references.citation: Science. 2011 Apr 8;332(6026):243-7
references.pmid: 21436399
references.citation: J Biol Chem. 2011 May 6;286(18):16516-24
references.pmid: 21454592
references.citation: Ann Neurol. 2011 Dec;70(6):943-54
references.pmid: 22069219
references.citation: J Exp Med. 2005 Aug 15;202(4):473-7
references.pmid: 16087714
references.citation: Mediators Inflamm. 1994;3(3):229-34
references.pmid: 18472948
references.citation: Nat Rev Neurol. 2010 Jul;6(7):383-92
references.pmid: 20639914
references.citation: J Cell Sci. 2012 Sep 15;125(Pt 18):4405-12
references.pmid: 22718347
references.citation: Immunomethods. 1994 Feb;4(1):25-34
references.pmid: 8069524
references.citation: J Clin Invest. 1997 Sep 1;100(5):957-62
references.pmid: 9276712
references.citation: Neurology. 2005 Apr 12;64(7):1270-2
references.pmid: 15824362
references.citation: Br J Pharmacol. 2004 Nov;143(6):725-32
references.pmid: 15504748
references.citation: Ann Neurol. 2012 Mar;71(3):314-22
references.pmid: 22271321